

**WILLOW BIOSCIENCES INC.  
NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING  
OF THE HOLDERS OF COMMON SHARES  
TO BE HELD ON APRIL 25, 2025**

**NOTICE IS HEREBY GIVEN** that the annual general and special meeting (the "**Meeting**") of the holders (the "**Shareholders**") of common shares (the "**Common Shares**") in the capital of Willow Biosciences Inc. (the "**Corporation**") will be held at the offices of Stikeman Elliott LLP, 4200 Bankers Hall West, 888 - 3rd Street S.W., Calgary, Alberta, T2P 5C5 on April 25, 2025 at 2:00 p.m. (Calgary time). Shareholders will also be permitted to view the Meeting virtually at the following link: <https://us02web.zoom.us/j/82537835429>, however there will be no opportunity for Shareholders to participate at the Meeting virtually. The Meeting is being held for the following purposes:

1. to receive the financial statements for the fiscal year ended December 31, 2024, and the report of the auditors thereon;
2. to fix the number of directors to be elected at five;
3. to elect directors for the ensuing year;
4. to appoint the auditors of the Corporation to hold office until the next annual meeting of the Shareholders and authorize the directors to fix their remuneration;
5. to consider, and if deemed advisable, to pass, with or without variation, a special resolution, substantially in the form set out in the accompanying management information circular dated March 24, 2025 (the "**Information Circular**"), authorizing and approving the proposed sale of the shares of Epimeron USA, Inc., the Corporation's wholly owned subsidiary, to Mycofeast Ltd., (the "**Sale Transaction**") which sale would constitute the disposition of all or substantially all of the undertaking of the Corporation, in accordance with Section 190 of the *Business Corporations Act* (Alberta) (the "**ABCA**"), as more particularly described in the Information Circular;
6. to consider, and if deemed advisable, to pass, with or without variation, a special resolution, substantially in the form set out in the Information Circular, authorizing and approving the Board to, at its sole discretion, amend the articles of the Corporation to change the name of the Corporation from "Willow Biosciences Inc." to "2482118 Alberta Ltd.", or such other name as may be approved by the Board at the time of implementation, subject to the completion of the Sale Transaction, as more fully described in the Information Circular;
7. to transact such other business as may properly come before the meeting or any adjournments thereof.

Only Shareholders of record at the close of business on March 24, 2025 (the "**Record Date**") are entitled to notice of and to attend the Meeting or any adjournment or adjournments thereof and to vote on the matters set out above, unless, after the Record Date, a holder of record transfers his or her Common Shares and the transferee, upon producing properly endorsed share certificates or otherwise establishing that he or she owns such Common Shares, requests, not later than 10 days before the Meeting, that the transferee's name be included in the list of Shareholders entitled to vote such Common Shares, in which case such transferee shall be entitled to vote such Common Shares as set out below.

**Registered Shareholders are requested to date and sign the enclosed form of proxy (the "Form of Proxy") and return it to the Corporation's transfer agent, Odyssey Trust Company. To be effective, the Form of Proxy must be mailed so as to reach or be deposited with Odyssey Trust Company, at Traders Bank Building 702, 67 Yonge Street Toronto, Ontario, M5E 1J8, Attention: Proxy Department or by fax at (800) 517-4553 not later than forty-eight (48) hours (excluding Saturdays, Sundays and statutory holidays in the Province of Alberta) prior to the time set for the Meeting or any adjournment thereof or may be accepted by the Chair of the Meeting at his discretion prior to the commencement of the Meeting. The Form of Proxy or other instrument used to appoint a proxy shall be executed by the Shareholder or their attorney, or if such Shareholder is a corporation, under the corporate seal, and executed by a director, officer or attorney**

thereof duly authorized. Alternatively, a registered Shareholder may complete their Form of Proxy online at <https://vote.odysseytrust.com> by following the instructions provided on the Form of Proxy.

**In order to ensure as many Common Shares as possible are represented at the Meeting, the Corporation strongly encourages registered Shareholders to complete the Form of Proxy and return it as soon as possible in accordance with the instructions outlined above (in bold).** Shareholders who do not hold their Common Shares in their own name are strongly encouraged to complete the voting instruction forms received from their broker as soon as possible and to follow the instructions set out in the accompanying management information circular dated March 24, 2025 (the “**Information Circular**”).

Shareholders may join the Meeting via webcast by following the below instructions. While the instructions will allow you to listen to the Meeting and ask questions, you will not be able to vote at the Meeting through the webcast, which is why the Corporation urges Shareholders to complete the Form of Proxy or other voting instruction form provided by your broker in accordance with the instructions outlined in the Information Circular.

The Information Circular relating to the business to be conducted at the Meeting accompanies this Notice.

Calgary, Alberta  
March 26, 2025

**BY ORDER OF THE BOARD OF DIRECTORS**

*(signed) “Jim Lalonde”*

---

**Jim Lalonde**

Chairperson of the Board